Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Safety and immunogenicity of one and two doses of the live, attenuated oral ETEC candidate vaccine BB01 in healthy adults - a phase I, randomized, double-blind study
ISRCTN ISRCTN05087777
ClinicalTrials.gov identifier
Public title Safety and immunogenicity of one and two doses of the live, attenuated oral ETEC candidate vaccine BB01 in healthy adults - a phase I, randomized, double-blind study
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis Vaccination with an oral live attenuated EnteroToxigenic Escherichia Coli (ETEC) candidate vaccine is safe and well tolerated and immunogenic.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Switzerland
Disease/condition/study domain ETEC disease.
Participants - inclusion criteria Healthy adults between 18 and 45 years of age.
Participants - exclusion criteria Any confirmed or suspected immunosuppressive or immunodeficient condition or prior exposure to ETEC.
Anticipated start date 13/05/2005
Anticipated end date 13/01/2006
Status of trial Completed
Patient information material
Target number of participants 50
Interventions 1. Single dose of ETEC candidate vaccine
2. Two doses of ETEC candidate vaccine
Primary outcome measure(s) Safety as measured by the incidence of adverse events reported post-vaccination.
Secondary outcome measure(s) 1. Seroconversion rates as determined by antibody titers pre- and post-vaccination against ETEC candidate vaccine antigens
2. Responder rates as determined by the number of antibody secreting cells pre- and post-vaccination against ETEC candidate vaccine antigens
3. Shedding of ETEC candidate vaccine strain post-vaccination as measured by duration and number of bacteria shedded
Sources of funding Berna Biotech Ltd (Switzerland)
Trial website
Publications
Contact name Dr  Robin  McKenzie
  Address Center for Immunization Research
Department of International Health
Johns Hopkins University
Bloomberg School of Public Health
  City/town Baltimore
  Zip/Postcode 21205
  Country United States of America
Sponsor Berna Biotech Ltd (Switzerland)
  Address Rehhagstrasse 79A
  City/town Bern
  Zip/Postcode 3018
  Country Switzerland
  Sponsor website: http://www.bernabiotech.com
Date applied 14/09/2005
Last edited 14/02/2008
Date ISRCTN assigned 19/10/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central